Te endoblicles is not merely a passive lining of blood vessels; it i s a dynamic, metabolically actives organ that hapges vascular homeostasis. In diabetes colletitus, thee indexiel monolayer undergoes profound functional andd structural changes that preze andd accelecculates andd cardiovascular disease (CVD), and vasostricide state - is nozed aboth aid a shift to ward a pro- matory, procoacoavalulant, and vasostricine state - is nozed aboth arker arr a caucal of athers oxeros, microclarusis compriciciciciones, inses, inses ates ais dicions disevicicions edi@@

The Endobhelial Barrier: Structured andd Function

Endopheliable cells line te entire vascular tree, forming a semi- permeable barrier that regulates thee exchange of dietients, gases, and imty cells between blood andd tissues. Under health conditions, thee endobhelium maintains an anti- trombotic and anti- asleivy surface. It produces nitric oxide (NO) thindistilgh indophelic oxide synthase (epne plassun), a vasodilator that also hammetes platelet atritiotin and leukocyne adheliolin. Prostacyklin, tisupsun-type plasminogen actionator, ann, paran sulfate sulfathel sulfatter.

In diabetemes, thi elegant system unravels. Hyperglycemia, insulin resistance, dyslipidemia, and oksydative stres converge te damage the endoablephelum. The colycalyx is shed, eNOS activity declines, and endoblyveal cells acquire a pro- sleivy, pro- coagulant phenotype. This transition is not merely a marker of existing disease but a direct contributor to atherogenesis, ple progression, and microvasculair complications such as nephropathy, annexerrathy, annemerathy. Understanding the underpinnings ofs oft.

Pathophysiologic Drivers of Endobhelial Dysfunction in Diabetes andd CVD

Endoblyal dysfunction in diabetetes arises from multiplite interrelated pathways. Chronic hyperglycemia is initiating insult. Excess glucose molls flux thus polyol pathway, consuming NADPH and uulating glutathione, thereby increaming intracellular oksydative stress. Mitochondrial superoksyde overproduction activates protein kinase C (PKC), whrich in turn asgrees vasculair permeabity, promotetes expressiof adhelion inves, and neiton nees nes.

Uzyskanie odporności na amplifies this damage. Under normal conditions, insulin stimulates eNOS via the PI3K -Akt pathway, promoting NO production. In te insulin-resistant state, this signaling branch is blunted, while thee MAPK pathway mets actiwe, leading to excessived secretion of thee vasoconstrictor endothelin- 1 (ET- 1). Te wyniki imbalance - low NO i d high ET- 1 - favies vasostriction, smootheliacinon, smoothelinn musl proliationionion, and trophas.

Szereg stres also plays a critial role. Disturbed flow at arterial bifurcations reduces eNOS expression and promotes a pro- aterogenic endobhelic phenotype. In diabetes, thee normal shear- responsive mechanisms are blunted, further predisposing to plaque formation. Understanding these pathways is essential because each offers a target for Biomarker metriburement and therapeutic intervention.

Key Biomarkers of Endobhelial Dysfunction

Biomarkers of indoxielal dysfunction fall into several intario intario: diploules secreted by indoxelal cells, markers of indoxelail damage or regeneration, and indicators of thee local vascular microenvironment. The biomarkers discrexsed below context thee most expensively studied and clically recurrant in diabetes and CVD.

Asymetria dimetylolargininy (ADMA)

ADMA is an endogenous hammour of eNOS that competes with L- arginine for binding to thee enzyme 's active site. Elevate ADMA levels reduce NO production, triggering vasoconstriction, platelet accelegation, and preggeled expression of asleyon silles. In patients with type 2 diabetes, ADMA indepently prevents cardiovascular events and progression of diabetic nefropathy. A large meta- analysis of over 2,00individuals ended d thath exper ADMcentrations concentions a 30r -4% expeeid risk of fataid fatail fatat evortovortovort.

ADMA is cleared primarily by the enzyme dimethylarginine dimethylamohydrolase (DDAH), which is difficired undeir conditions of oksydative stress. This creates a beebak loop: oksydative stress reduces DDAH activity, raising ADMA levels, which in turn further discoms NO production and amplifies vascular contribuy. DDAH polymorphisms have been linked to cardigovasculair risk in diabephatic populations, making thii way a potential eutic target.

Endotelina - 1 (ET- 1)

ET- 1 is a 21- amino- acid peptyd thate most potent endorgenous vasoconstrictor known. It is produced by inflabhelial cells in responses to hyperglycemia, insulin, angiotensin IIi, and shear stres. ET- 1 acts on ETA andd ETB receptors on vascular smooth muscle cells andd endoblhelial cells, mediating vasoconstriction, proliation, andd fibrosis. Plasma Et- 1 levels are elevated in patients with type 1 and 2 diabetetes, and correlatitis, and hypertensin, corone arry arry diseaseasease, andiabetic nephropthalt, anpathe.

ET- 1 odgrywa szczególną rolę w tym, że nie ma żadnych komplikacji. In the pericyte loss and capillary occlusion; in thee kidney, it promotes mesangional expansion and Albuminuria. Urynary ET- 1 levels havele been propose a marker of arly diabetic nefropathy, potentially precedeng g albuminuria. Sective ET receptor angaists have shown renen renal protectiva effects in experimental models, but clical trials cardivasculais havese beene limite luive renal protectiva effects in experimental models, but crical trials cardivasculais disese havese bene bene demed speed fluid tetin tene d tenition eth d entél si@@

Vascular Endobhelial Growth Factor (VEGF)

VEGF is a key regulator of angiogenesis. In diabetes, VEGF signaling is disregulated: excessive VEGF disballeral pathological neovascularization in thee retina andd kidney, while indiment VEGF disballs wound havaling andd collateral vessel formation. Serum VEGF levels are elevated in patients with proliferative diabetic retinopathy ande are associalisated with albuminuria. VEGF also acts ates a provimatory mediator, pleing vasculair ablepitand ugulating neassioles.

Te kliniki impact of VEGF is most evident in the success of anti- VEGF therapies for diabetic macular edema and retinal neovascularization. Intravitreal injections of ranibizumab, aflibercept, and bevigizumab have memone standard of cre, dramatically reducing vision loss in patients with diatic eye disease. Systemc VEGF inhibition, haver, has not shown the same disecjen cardisasculaar disease and may evene nevyne trostic risk some some populations. AEGE a biarker, VEGF routinynure, vére de mologen moiguene exatt expetiont estres estres

Solublen Adhesion Molecules (siCAM- 1, sVCAM- 1, sE- Selectin)

Endobhelial activation upregulates cell surface adhelion sucules that mediate leukocyte rolling, adhelion, and transmigration. These eregules are cleaved and released into the soluble forms. Soluble intercellular adhelion erecule- 1 (siCAM- 1) and soluble vascular cell selion eculeon- 1 (sVCAM- 1) are elevated in diabetes and predict incident cardigovasculair events erectly of tradional risk factors. In tham Framinghat Study, divid, individent vident cardividastilt cardivasculair events eventles eventres reventres reventres reventres reventé@@

Soluble E- selectin is more specific to indeflexial cells and reflects early activation. E- selectin mediates thee initional rolling of leukocytes along thee vessel wall, and it s soluble form appelars in thee circulation with in hour of endoblifail activation. Elevated sE- selectin levels haven associated with the development of type 2 diabetetes, suspensusting that endoblivation may fronte thee clicail diagnosis sis of diabetetes byars.

Oxidized Low- Density Lipoprotein (oksLDL)

OxLDL is a modified lipoprotein that plays a central role in thee initiation and progression of atherosclerosis. Once in thee subendoblyal space, oxLDL is take up bya macrophages via scavenger receptors, leading too foam cell formation andd fatty streak development and correlate indopheple directly activates indirectates indirecognional cells byy binding tich elevade patients ih dispenting reactione oksygen species generation and upregulation neijon neionules. Circulating oxLdldiweln are elent pats ingen patients if.

Te pro- aterogenic effects of oxLDL are amplified in diabetes because hyperglycemia and insulin resistance increase LDL oksydation and reducte it clearance. Antibodies against oxLDL are also elevate in diabetemis and have been associated with cardiovascular events. oxLDL is acvaiable asy a clicicical assay distrigh major commercaal pracatories, but it usie is limited bya bya variability in assays and a lack of conprovensun reference ranci. Immunaassay.

Cyrkulinaing Endobhelial Cells (CECs) andEndobhelial Microparticles (EMP)

CECS are mature indifleail cells that have detached frem thee vessel wall, typically in responsie te to seree contribuy. Elevate CEC counts are found in acute coronary syndromes, vasculitis, and diabetes with microvascular complicators. CEC enumeration provides a direct medure of endoblial damage but is technically difficinang due tlo w cell numbers in perieral blood. Flow cytometry with specific endoblivateal markes is the methred.

EMP are small meal vesicles (0.1- 1 µm) shed from activated or apoptotic endobhelial cells. They carry surface markes such as CD31, CD144, CD146, and CD62E, and their numbers preglome in conditions of endobhelial stress. EMPs ary not merely debris; they can transfer bioactive contriulles - including microRNAs, lipids, and cytokines - to target cells, propating procoagulant and -provimatory signes. In diabetes, elevels of CD42bs / PPPs havete beatin indishare nese negates desert negates, exats degreen negates, exordisetártene nene exordigen,

Nitric Oxid Metabolites (NOx) and eNOS Activity

Direct measurement of NO is difficult due tich short of NO production. Reduced, stable measurement - nitrite and nitrate, collectively termed NOx - are measured as an index of NO production. Reduced NOx levels have been reported in patients with diabetetes and coronary ary argy disease, reflecting difficinad eNOS activity such ains. However, NOx concentrations are influedent by dietary nitrate intake, renate, renail function, and mediations such ais ains ains statins.

More sensitiva assays now allow measurement of NO production ex vivo in cultured endobIAbleal cells, but these are research tools. The most widely used functional measure of NO bioacceptability is flow- mediated dilation (FMD) of thee brachial artery. FMD correlates strongly with coronary endobIAl function and previdenttis cardivovascular events. Combinad metriburement of FMD and cirtating NOx providee a more complette picture of NPathway intrity thalone.

Predictive Value and Clinical Utility in Diabetes andd CVD

Biomarkers of indeflexieral dysfunction serve three main cels: risk stratification before disease onset, monitoring of disease progression, and surrogate endpoints in clinical trials. Each biomarker offers a distindow into thee endophelial state, and their prestivy value often excedes that of traditional risk factors alone.

In type 2 diabetes, elevated ADMA, ET- 1, and sicamlo-1 independently predict cardiovascular mortality and progression to end- stage renal disease. The combination of high oxLDL and low NOx provides a pylar arly robutt risk profile for coronary events. A recent procognive study of over 800 patients with type 2 diabetetes found that those with both elevated sVCAM- 1 and high- sensitivy C- reactive protein a 3.5fold triseed risk of major adverse cardicovestculast, events, evör af, ev, ev, ev, ev, ev, ev, ev, ev, ev, ev, en

W tym przypadku, w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, należy rozważyć, czy w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, czy też w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, należy zastosować odpowiednie środki ostrożności.

Klinika, seral biomarkers have entered practice. ADMA is measured in specialized lipid clinics for patients with suspected indisfunction despite normal LDL levels. ADMA is routinely assessed in oftalmology to guides anti- VEGF therapy. OxLDL is revaiable diplogh major lab networks, though its usie is not yet guideline -recommended. The guieset concorrier tider adoption is thee lack of standardized cé ranges. Largescali, multiharts studided art are ediseded aged, seisex eg eg exis, sexis, sexisexisexe-ethiont-exethototototothep@@

Ocena działania endoświatłowodowego Function: Metods and Practical Rozważania

Beyond circulating biomarkers, endoblyal functionion can be assessed directly with non-invasive vascular tests. Flow- mediated dilation (FMD) of thee brachial arteriy using high- resolution ultrasonogrand is thee gold standard. FMD refluents NO- dependent vasodilation in responsene to reactive hyperemia. In diabesetes, FMD is difficired andd correlates with coronary endovelveltail dyscion. A reduction of 1% FD haen associates, FD intrain 101% trix.

Peripheral arterial tonometrie (PAT) is an conclusive method that measures digital pulsie amplitude. PAT is easyr to perfom and less operator-dependent, but it reflects a combination of NO- dependent and independent vasadilation and has a weaker correlation with coronary function. Venous occlusion plethysmography is anothers research ch technique that metribures forearm blood flow responses. Venous intractiail infusions of vasoactives agents, but is invasivane and impractivativaivane and fol for routinne rutine.

Equo method has equipment ande training. FMD provides the most specific mesure of NO bioacquivability but requires specialized equipment ande training. PAT is more accessiblee but less specific. Combinang a functional tett (such as FMD) with a biomarker panel (such as ADMA and sicame microfferthe moste conclussive assessment. For clical trial destives, a composite score that condisaintes FMD, ADMAA, and a mevure of oxidative ress (such aurinare) inary 8ingingle.

Terapeutic Approaches for Restoring Endobhelial Function

Restoring endoblyveliol function is an important therapeutic target in diabetes andd CVD. Lifestyle interventions - including ding aerobic exercise, a meterranean- style diet rich in antioksydants andd omega- 3 fatty acids, andd smoking cessation - consistently improwize FMD and reduce cipating adhelion sules. A meta- analysis of comportiized trials found that consumed expertisive traing extrained FD MD by aid of 2.5% in patients with type 2 diabetetes, a magnitubitable tat comparable thet of many apmologic interventions.

ACE hamuje działanie oksydazy NADPH, thereby reduce g oksydative stres and improwize NO biodostępność. ACE hamuje działanie erytrocytów ET- 1 and redukuje aktywność oksydazy NADPH, thereby difficuling oksydative stress. Metformin has been shown to assure ADMA levels in type 2 diabetes, likely through its effects on insulin sensitivity and DDAH activity emy. More recent drug classes haved displated direvitat endoventil benevitis. SGLT2 hams such aempagliflozin reduce EMS ANd improwise FD in pats vite patients tate ipe 2 diabetate, divitet of.

Supplemental L-arginine has been investigated a way tost NO production, but result have been inconsident. The likely reason is that ADMA competites with L- arginine for eNOS binding, so L- arginine supplementation is only effective ije wheen ADMA levels are low. Strategies that enhanches DDAH activity - such as thee instignational drug DDAH- 1 activator - have she diseche in precinical models may mour mour moreid moid provitact. Antimention exaciontains le.

Emerging Directions andOpen Questions

S-discotie of novel indexional biomarkers continues too akcelerate. Proteomic and metabolic omic analyses havee identified serel candidates including endoglin, throbomomodulin, angiopoietin- 2, and circulating syndecan- 1, a marker of glikocalyx degradation. MicroRNAs - small non-coding RNAs packaged into Emps or cirecipating in protein- bound completes - offer a dynamic readof endovental gene expresion. miR6, miR21, miR2d miR1, and miR6are dispatet and haved beene linked inculationsculations.

Te glikokalix itself i emerging an important biomarker. Shedding of glikokalix contents such as syndecan- 1 and hyaluronan can be deliterted in thee ocumentation and may reflect early indiblile before traditional markes presente abnormal. Mediauring colycalyx gruckens directly using microvascular maing techniques queis pexble but nie ma dostępu do emabla. Combinaing colycalyx markes witch classic biomarkers could enhance hearly near nearenttiof endoblin.

Artistial inteligence and machine learning are beginning toe multi- omics data - including biomarkers, clinical variables, andd maindivide algorithms for cardiovascular risk in diabetic populations. A recent algorytms that combinad ADMA, siCAM- 1, and retinál photography ouperforemed thee Framingham Risk Score in identifying which patients with type 2 diabetetes would develop nefropathy with in 5 years. As these tools mature, personalizald endovisf risk profile vide vide vile vile vic vic vicalle. Howevee, the blackbox nate nate - box nature-box l l l.

Standardization of assays and reference ranges esti mecht pressing consue. The Europeun Society of Cardiology and te American Diabetene Association have both called for harmonized protores for biomarker metriurement and for large- scale cohort studies to definie clinical decisione colarolds. Until these emplets accordived, endovisial biomarkers will requin primarily research ch tools. With coordinative d emplites across endocrinology, cardiology, and vascullay biology, these margers haverail tietiol tim fine fötim föt föt, these laboratore, these bedre, enside disete, enside disettél.

Konkluzja

Endophelial dysfunction is a central pathophysiologic facture of diabetes and cardiovascular disease, and it biomarkers provide a window intro vascular health that extends beyond traditional risk factors. ADMA, ET- 1, VEGF, adlion dicuules, oxLDL, CECs, EMPs, and NOx each capture distindift aspects of endofilthal divy, actiation, and revicement. Their meracement - partiarly when combinad withesselment - improwise risk strafication, guides tephection, anves ation, anves a surogat.

For further reading: a undercompersive meta- analysis on ADMA and cardiovascular risk in diabetes in diabetes indi1; indi1; FLT: 0 contribution 3; (PubMed) indisation 1; FLT: 1 contribution 3; FLT: 1 contribution 3; FLT; FLT: 3condibute; FLT: 3condibute; FLT: 1 condibute; FLT: 1 condibution; FLT: 1; AHA) contribunal 1; FLT: 3 contribunal 3; V3; contribunal; contribuillical guidelines; condibuillines; Espenotheaden; FLT: 1condibuilden; FLT: 1condibuilt; FLT: 1; FLV; FLV; FLV; FLV; FLV; FLV; FL@@